Products Categories
| CAS No.: | 551-11-1 |
|---|---|
| Name: | Prostaglandin F2a |
| Molecular Structure: | |
|
|
|
| Formula: | C20H34O5 |
| Molecular Weight: | 354.487 |
| Synonyms: | (+)-ProstaglandinF2a;7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid;9a,11a,15(S)-Trihydroxy-5-cis-13-trans-prostadienoic acid;9a,11a-PGF2;9a,11a-PGF2a;Amoglandin;Cyclosin;Cyclosin (pharmaceutical);Dinifertin;Dinoprost;Enzaprost;Enzaprost F;Glandin N;PGF2a;Panacelan;Prostaglandin F2;Prostaglandin F2a;Prostamate;Prostarmon F;Prostin F 2 alpha;Protamodin;U 14583; |
| Density: | 1.153 g/cm3 |
| Melting Point: | 25-35° |
| Boiling Point: | 531 °C at 760 mmHg |
| Flash Point: | 289 °C |
| Appearance: | White to off-white crystalline solid |
| PSA: | 97.99000 |
| LogP: | 3.04290 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 551-11-1
dinoprost
| Conditions | Yield |
|---|---|
| With hydrogenchloride In water; acetone at 20℃; for 0.333333h; Inert atmosphere; | 99% |
- 55022-57-6
methyl (5Z)-7-{(1R,2R,3R,5R)-5-acetoxy-3-hydroxy-2-[(1E,3S)-3-hydroxy-1-octenyl]cyclopentyl}-5-heptenoate
- 551-11-1
dinoprost
| Conditions | Yield |
|---|---|
| With sodium hydroxide In tetrahydrofuran; methanol Ambient temperature; | 95% |
| With sodium hydroxide In tetrahydrofuran; methanol at 20℃; for 2h; |
- 33854-16-9
(+)-prostaglandin F2α
- 551-11-1
dinoprost
| Conditions | Yield |
|---|---|
| With water In tert-butyl methyl ether at 35℃; for 18h; Enzymatic reaction; | 90% |
| base hydrolysis; Yield given; |
- 1239683-12-5
(Z)-7-((1R,2R,3R,5S)-3-[(tert-butyldimethylsilanyl)oxy]-2-{(S,E)-3-[(tert-butyldimethylsilanyl)oxy]oct-1-en-1-yl}-5-hydroxycyclopentyl)hept-5-enoic acid
- 551-11-1
dinoprost
| Conditions | Yield |
|---|---|
| With hydrogen fluoride; water In acetonitrile at 20℃; for 7h; stereoselective reaction; | 90% |
| With hydrogenchloride In tetrahydrofuran; water at -78 - 20℃; for 6h; | 89% |
| With hydrogenchloride In tetrahydrofuran; water at 20℃; for 6h; Inert atmosphere; | 89% |
- 145313-85-5
(Z)-7-[(1R,2R,3R,5S)-3-Benzyloxy-2-((E)-(S)-3-benzyloxy-oct-1-enyl)-5-hydroxy-cyclopentyl]-hept-5-enoic acid
- 551-11-1
dinoprost
| Conditions | Yield |
|---|---|
| With ammonia; sodium | 75% |
| Conditions | Yield |
|---|---|
| With (Z)-2-Butene; C37H40Cl2N2ORuS2 In tetrahydrofuran at 22℃; under 7 Torr; Pressure; Inert atmosphere; Glovebox; Sealed tube; | 75% |
- 51388-75-1, 59829-49-1, 59829-50-4, 59829-51-5, 59829-52-6, 85550-76-1, 85550-82-9, 136235-23-9, 136235-24-0
(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol
- 17814-85-6
(4-carboxybutyl)triphenylphosphonium bromide
- 551-11-1
dinoprost
| Conditions | Yield |
|---|---|
| With potassium tert-butylate In tetrahydrofuran at 20℃; Wittig Olefination; | 55% |
| Stage #1: (4-carboxybutyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran at 0℃; for 0.666667h; Wittig Olefination; Schlenk technique; Inert atmosphere; Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 20℃; for 1h; Wittig Olefination; Schlenk technique; Inert atmosphere; | 152 mg |
| Stage #1: (4-carboxybutyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran at 0℃; for 0.666667h; Inert atmosphere; Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 0 - 20℃; for 1h; Inert atmosphere; | 152 mg |
| Stage #1: (4-carboxybutyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran at 0℃; for 0.666667h; Wittig Olefination; Schlenk technique; Inert atmosphere; Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 0 - 20℃; for 1.5h; Wittig Olefination; Schlenk technique; Inert atmosphere; | 24.8 mg |
| Stage #1: (4-carboxybutyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran at 0℃; for 0.666667h; Inert atmosphere; Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 0 - 20℃; for 2h; Inert atmosphere; | 70 mg |
- 51388-75-1, 59829-49-1, 59829-50-4, 59829-51-5, 59829-52-6, 85550-76-1, 85550-82-9, 136235-23-9, 136235-24-0
(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol
- 39968-97-3
(4-carboxybutylene)triphenylphosphorane
- 551-11-1
dinoprost
| Conditions | Yield |
|---|---|
| Stage #1: (4-carboxybutylene)triphenylphosphorane With potassium tert-butylate In tetrahydrofuran at 0 - 5℃; for 0.666667h; Inert atmosphere; Stage #2: (3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol In tetrahydrofuran at 20℃; for 1h; | 54% |
- 51388-75-1, 59829-49-1, 59829-50-4, 59829-51-5, 59829-52-6, 85550-76-1, 85550-82-9, 136235-23-9, 136235-24-0
(3aR,4R,5R,6a5)-4-[(E,3S)-3-Hydroxy-1-octenyl]perhydrocyclopenta[b]fura n-2,5-diol
- 41723-91-5
4-carboxybutyliden triphenylphosphorane sodium
- 551-11-1
dinoprost
| Conditions | Yield |
|---|---|
| 53% |
| Conditions | Yield |
|---|---|
| In water for 0.166667h; Gersemia fruticosa preparation, pH 8.5; | A 20% B 20% C 20% |
What can I do for you?
Get Best Price
Consensus Reports
Specification
The Prostaglandin F2α, with the CAS registry number 551-11-1, is also known as l-Prostaglandin F2-alpha. It belongs to the product category of Prostaglandins. This chemical's molecular formula is C20H34O5 and molecular weight is 354.48096. Its IUPAC name is called (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid. This chemical's classification codes are Abortifacient Agents; Abortifacient agents, nonsteroidal; Drug / Therapeutic Agent; Hormone; Human Data; Mutation data; Oxytocic; Oxytocics; Prostaglandin; Reproductive Control Agents; Reproductive Effect.
Physical properties of Prostaglandin F2α: (1)ACD/LogP: 2.14; (2)ACD/LogD (pH 5.5): 1.33; (3)ACD/LogD (pH 7.4): -0.47; (4)ACD/BCF (pH 5.5): 3.86; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 53.76; (7)ACD/KOC (pH 7.4): 1; (8)#H bond acceptors: 5; (9)#H bond donors: 4; (10)#Freely Rotating Bonds: 15; (11)Index of Refraction: 1.569; (12)Molar Refractivity: 100.75 cm3; (13)Molar Volume: 307.3 cm3; (14)Surface Tension: 48.6 dyne/cm; (15)Density: 1.153 g/cm3; (16)Flash Point: 289 °C; (17)Enthalpy of Vaporization: 92.76 kJ/mol; (18)Boiling Point: 531 °C at 760 mmHg; (19)Vapour Pressure: 1.71E-13 mmHg at 25°C.
Preparation: In domestic mammals, it is produced by the uterus when stimulated by oxytocin, in the event that there has been no implantation during the follicular phase.
Uses of Prostaglandin F2α: Prostaglandin F2α is pharmaceutically termed Dinoprost is a naturally-occurring prostaglandin used in medicine to induce labor and as an abortifacient.
You can still convert the following datas into molecular structure:
(1)Canonical SMILES: CCCCCC(C=CC1C(CC(C1CC=CCCCC(=O)O)O)O)O
(2)Isomeric SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O
(3)InChI: InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
(4)InChIKey: PXGPLTODNUVGFL-YNNPMVKQSA-N
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intramuscular | 152mg/kg (152mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 2, Pg. 403, 1971. |
| mouse | LD50 | intravenous | 56mg/kg (56mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 2, Pg. 403, 1971. |
| mouse | LD50 | oral | 1300mg/kg (1300mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 2, Pg. 403, 1971. |
| mouse | LD50 | subcutaneous | 212mg/kg (212mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 2, Pg. 403, 1971. |
| rabbit | LD50 | intramuscular | > 10mg/kg (10mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) LUNGS, THORAX, OR RESPIRATION: CYANOSIS | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 9, Pg. 261, 1978. |
| rabbit | LD50 | intravenous | 2500ug/kg (2.5mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) LUNGS, THORAX, OR RESPIRATION: CYANOSIS | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 9, Pg. 261, 1978. |
| rat | LD50 | intramuscular | 112mg/kg (112mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 2, Pg. 403, 1971. |
| rat | LD50 | intravenous | 106mg/kg (106mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 2, Pg. 403, 1971. |
| rat | LD50 | oral | 1170mg/kg (1170mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 2, Pg. 403, 1971. |
| rat | LD50 | subcutaneous | 95mg/kg (95mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 4, Pg. 193, 1973. | |
| women | TDLo | intravenous | 20ug/kg (0.02mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING | Japan Medical Gazette. Vol. 10(7), Pg. 9, 1973. |